Volume 26, Issue 1, Pages (January 2018)

Slides:



Advertisements
Similar presentations
Gene Preference in Maple Syrup Urine Disease Mary M. Nellis, Dean J. Danner The American Journal of Human Genetics Volume 68, Issue 1, Pages (January.
Advertisements

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.
Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Volume 20, Issue 2, (February 2012)
414. A Novel Clinical Severity Scoring Measure in Canine X-Linked Myotubular Myopathy: Results Following Systemic AAV Gene Replacement    Molecular Therapy 
Volume 7, Issue 1, Pages (January 2003)
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Engineering Natural Killer Cells for Cancer Immunotherapy
Genome-editing Technologies for Gene and Cell Therapy
627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase    Molecular Therapy  Volume.
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Volume 25, Issue 10, Pages (October 2017)
Volume 15, Issue 1, Pages (January 2007)
Evolving Gene Therapy in Primary Immunodeficiency
Engineering Natural Killer Cells for Cancer Immunotherapy
Escaping the Valley of Death
Volume 26, Issue 2, Pages (February 2018)
Volume 25, Issue 1, Pages 5-7 (January 2017)
Xiuyan Wang, Isabelle Rivière  Molecular Therapy - Oncolytics 
Volume 152, Issue 1, (January 2013)
Molecular Therapy - Methods & Clinical Development
724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.
Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals  Clare Pridans,
Volume 8, Issue 6, Pages (December 2003)
Genome-editing Technologies for Gene and Cell Therapy
Molecular Therapy - Methods & Clinical Development
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
The Pharmacology of T Cell Therapies
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
Defective Extracellular Matrix Reorganization by Chronic Wound Fibroblasts is Associated with Alterations in TIMP-1, TIMP-2, and MMP-2 Activity  Helen.
Generation of a stable packaging cell line producing high-titer PPT-deleted integration- deficient lentiviral vectors  Peirong Hu, Yedda Li, Mark S Sands,
Adenovirus Virion Stability and the Viral Genome: Size Matters
Molecular Therapy - Methods & Clinical Development
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Designer Lipids Advance Systemic siRNA Delivery
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
Erratum The American Journal of Human Genetics
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
Volume 26, Issue 2, Pages (February 2018)
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Volume 26, Issue 1, Pages (January 2018)
Volume 26, Issue 1, Pages (January 2018)
Volume 22, Issue 1, Pages (January 2014)
Molecular Therapy - Methods & Clinical Development
405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement    Molecular.
Volume 26, Issue 4, Pages (April 2018)
Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Volume 25, Issue 1, Pages (January 2017)
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Volume 26, Issue 2, Pages (February 2018)
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?
History of Oncolytic Viruses: Genesis to Genetic Engineering
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Harry I Segall, Eunsun Yoo, Richard E Sutton  Molecular Therapy 
Volume 3, Issue 1, Pages 8-13 (January 2001)
Volume 8, Issue 2, Pages (August 2003)
Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?
Volume 148, Issue 1, (January 2012)
Molecular Therapy - Methods & Clinical Development
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Volume 26, Issue 1, Pages 280-288 (January 2018) Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products  Kenneth Cornetta, Lisa Duffy, Cameron J. Turtle, Michael Jensen, Stephen Forman, Gwendolyn Binder-Scholl, Terry Fry, Anne Chew, David G. Maloney, Carl H. June  Molecular Therapy  Volume 26, Issue 1, Pages 280-288 (January 2018) DOI: 10.1016/j.ymthe.2017.09.008 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 Schematic Representation of the RCL Assay T cell products are incubated with C8166-45 cells at a ratio of 1:5. Over half of test articles submitted contained approximately 1 × 108 T cells and were divided into twenty-five 300-cm2 flasks. Cultures were passed a minimum of 5 passages using increasingly smaller vessels. After 3 weeks, cells were placed in fresh media, and conditioned media were harvested after 24 hr. Media from all amplification cultures are pooled, and two aliquots are then incubated with naive C8166-45 cells. After 7 days, culture media were analyzed for p24 antigen by ELISA and either the psi-gag PCR assay or PERT. The figure depicts amplification of a low-titer RCL present in the test article. Molecular Therapy 2018 26, 280-288DOI: (10.1016/j.ymthe.2017.09.008) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions